Get the Stockscreener App
2.84
0.35%
-0.01
Neuraxis Inc stock is traded at $2.84, with a volume of 66,142.
It is down -0.35% in the last 24 hours and up +18.33% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.85
Open:
$2.68
24h Volume:
66,142
Relative Volume:
2.51
Market Cap:
$19.82M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.521
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+12.70%
1M Performance:
+18.33%
6M Performance:
-4.70%
1Y Performance:
+16.83%
1-Day Range:
$2.665
$3.12
1-Week Range:
$2.48
$3.12
52-Week Range:
$2.0001
$3.89
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.84 | 19.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuraxis Inc Stock (NRXS) Latest News
NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com
UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN
Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR
Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors - The Manila Times
NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire
NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan
NeurAxis, Inc. Reports Strong Preliminary Unaudited Fourth Quarter 2024 Results - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year - Marketscreener.com
Everything Blockchain Inc. Announces Letter to Shareholders from CEO - The Manila Times
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth - GlobeNewswire
NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan
NeurAxis (NASDAQ:NRXS) Shares Down 4.1% – What’s Next? - Defense World
Model N Appoints New Chief Executive Officer, Bret Connor - The Manila Times
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - GlobeNewswire
NeurAxis CEO to Present at Lytham Partners 2025 Healthcare Investor Summit - StockTitan
MicroCap Opportunities 2024 Year-End Portfolio Update - substack.com
FDA Approvals News Live Feed - StockTitan
Vagus Nerve Stimulators Market Growth in Future Scope 2024-2031 - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
NeurAxis Inc. Announces FDA 510(k) Clearance of Red for Testing and Evaluation of Patients with Chronic Constipation - Marketscreener.com
Connyct Launches on iOS: Build Your College Crew, Share Your Vibe, and Never Miss a Party - The Manila Times
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for - GlobeNewswire
NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device - StockTitan
FDA Awards New Clearance to NeurAxis’ IB-Stim - MPO-mag
Rosalind Advisors, Inc. Acquires Significant Stake in Neuraxis I - GuruFocus.com
Neuraxis increases Series B Preferred Stock and extends dividend rights By Investing.com - Investing.com South Africa
Neuraxis increases Series B Preferred Stock and extends dividend rights - Investing.com
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage - MSN
Critical Review: BioSig Technologies (NASDAQ:BSGM) vs. NeurAxis (NASDAQ:NRXS) - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Q3 2024 Earnings Call Transcript - MSN
Neuraxis secures $5 million in preferred stock sale By Investing.com - Investing.com Nigeria
Neuraxis secures $5 million in preferred stock sale - Investing.com
Neuronetics Grants Inducement Awards to New Employees - MSN
NeurAxis Stock Surges After Strong Q3 Earnings And Expanded Coverage - Barchart
Neuraxis Inc. (NRXS) Quarterly 10-Q Report - Quartz
NeurAxis reports 40% increase in revenues in Q3 2024 - Medical Buyer
NeurAxis Reports Strong Revenue Growth in Q3 2024 - TipRanks
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues - GlobeNewswire
NeurAxis Q3 Revenue Surges 40%, Expands Coverage to 35M Lives Amid FDA Milestone | NRXS Stock News - StockTitan
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - Building Indiana
NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 - GlobeNewswire
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.81%
Cap:
|
Volume (24h):